Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Mobile, Alabama 36688


The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both intravenous and oral panobinostat when given in combination with trastuzumab and paclitaxel. The study will evaluate safety and efficacy of the combination in adult female patients with HER2+ metastatic breast cancer


Inclusion Criteria: - Age > 18 year old - Confirmed HER2+ metastatic breast cancer - Prior treatment and progression on trastuzumab - Patients must have adequate organ functions - Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 Exclusion Criteria: - Patients who have had surgery within last 2 weeks prior to starting the treatment - Patients who receive concurrent therapy for brain metastases - Impaired heart function or clinically significant heart disease - Ongoing diarrhea - Liver or renal disease with impaired hepatic or renal functions - Concomitant use of any anti-cancer therapy or certain drugs - Female patients who are pregnant or breast feeding - Patients not willing to use an effective method of birth control Other protocol-defined inclusion/exclusion criteria may apply



Primary Contact:

Study Director
Novartis Pharmaceuticals
Novartis Pharmaceuticals

Backup Contact:


Location Contact:

Mobile, Alabama 36688
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.